CIAM
CMMB

Caitong International Asset Management’s Chemomab Therapeutics CMMB Stock Holding History

Caitong International Asset Management’s Portfolio CMMB Stock Details CMMB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$13 Hold
8
– – ﹤0.01% 2593
2026
Q1 		$13 Buy
+8
New +$14 ﹤0.01% 2112

Other funds holding CMMB

Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
KPWS
Kestra Private Wealth Services Austin, Texas $9.1B AUM 32.09% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
RhumbLine Advisers
RhumbLine Advisers Boston, Massachusetts $133B AUM 43.5% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return
PIP
Philadelphia Investment Partners Voorhees, New Jersey $161M AUM
Lido Advisors
Lido Advisors Los Angeles, California $36.8B AUM 26.6% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return

Caitong International Asset Management's CMMB Position: Q2 2026 in Review

Caitong International Asset Management held its Chemomab Therapeutics (CMMB) position steady in Q2 2026 at 8 shares worth $13. The position accounts for ﹤0.01% of the portfolio, ranked #2593.

Caitong International Asset Management first reported a position in CMMB in Q1 2026 and has held it in 2 quarters since. 13 funds tracked by Wall St. Rank hold CMMB as of Q2 2026.

  • Caitong International Asset Management held 8 shares of Chemomab Therapeutics worth $13 as of Q2 2026.
  • Caitong International Asset Management left its Chemomab Therapeutics share count unchanged in Q2 2026.
  • Chemomab Therapeutics made up ﹤0.01% of Caitong International Asset Management's portfolio in Q2 2026, its #2593 holding.
  • Caitong International Asset Management first reported a position in Chemomab Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 13 funds tracked by Wall St. Rank held Chemomab Therapeutics as of Q2 2026.

Based on Caitong International Asset Management's 13F filing for Q2 2026, filed 5 Aug 2026.